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Background: Previous trials have shown that lipid-lowering therapy can improve clinical outcomes and achieve regression of coronary plaques. The 
TRUTH study, a prospective, open-label, randomized multicenter trial, was designed to evaluate the effect of statins on coronary plaque composition 
in patients with anigina pectoris by using intravascular ultrasound with Virtual Histology(VH-IVUS) in Japan. The aim of this subanalysis was to 
examine the effects of statins on coronary plaques in patients with unstable angina.
Methods: Thirty-six patients with unstable angina and 83 patients with stable angina were assigned to either pitavastatin treatment (4mg/day, 
intensive lipid-lowering) or pravastatin treatment (20mg/day, moderate lipid-lowering). Non-treated plaques on treated vessels were evaluated by 
VH-IVUS at the time of PCI and after 24-40 weeks of statin therapy.
Results: Gray-scale IVUS analysis showed significant decrease of the plaque volume only in the pitavastatin group with unstable angina (9.46±3.1 
to 8.98±3.0 mm3/mm, P= 0.0013). In VH-IVUS analysis, the fibro-fatty component decreased in pitavastatin group with unstable angina (1.28±0.89 
to 0.78±0.71 mm3/mm, P=0.03), whereas did not changed in pravastatin group with unstable angina (1.16 ±0.86 to 0.96±0.92 mm3/mm, 
P=0.27). Among patients with stable angina, the fibro-fatty component tended to decrease both in pivastatin group and pravastatin group (pivastatin 
group , 0.998±0.87 to 0.817±0.55 mm3/mm, P=0.0512; pravastatin group, 1.01±1.1 to 0.79±0.83 mm3/mm, P=0.0438).
Conclusion: Intensive lipid-lowering therapy with pitavastatin may be more effective for stabilization and regression of coronary plaques especially 
in patients with unstable angina.
